XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]        
Revenue $ 51 $ 0 $ 51 $ 0
Cost of revenues 120 0 170 0
Gross loss (69) 0 (119) 0
Operating expenses:        
Research and development 1,457 4,963 4,710 8,430
General and administrative 3,979 3,341 10,081 14,060
Acquisition of Exacis in-process research and development 0 0 460 0
Impairment of in-process research and development 0 0 0 5,990
Total operating expenses 5,436 8,304 15,251 28,480
Loss from operations (5,505) (8,304) (15,370) (28,480)
Other (expense) income, net:        
Change in fair value of warrant liabilities 20 1,024 166 10,493
Change in fair value of contingent consideration 0 0 118 0
Loss on non-controlling investment 0 (21) (59) (932)
Other expense, net (114) (10) (369) (1,166)
Total other (expense) income, net (94) 993 (144) 8,395
Loss before income taxes (5,599) (7,311) (15,514) (20,085)
Benefit (provision) for income taxes 8 (5) (1) (5)
Net loss (5,591) (7,316) (15,515) (20,090)
Series A preferred stock dividend 0 0 (8) (8)
Net loss attributable to common stockholders $ (5,591) $ (7,316) $ (15,523) $ (20,098)
Net loss per common share - basic (in dollars per share) $ (1.03) $ (2.49) $ (2.94) $ (7.04)
Net loss per common share - diluted (in dollars per share) $ (1.03) $ (2.49) $ (2.94) $ (7.04)
Weighted average shares outstanding - basic (in shares) 5,410 2,941 5,281 2,855
Weighted average shares outstanding - diluted (in shares) 5,410 2,941 5,281 2,855